Neurology News

Imbrium Therapeutics LP, a subsidiary of Purdue Pharma LP, announced positive preliminary results from a phase 2 study of an investigational oral treatment for patients with insomnia during recovery from an alcohol use disorder.

Individuals with chronic sleep deprivation demonstrate a higher risk for developing systemic lupus erythematosus, with stronger effects in those with depression and bodily pain, according to data published in Arthritis Care & Research.

Biotechnology startup company Camellix has announced the discovery of a green tea-derived polyphenol molecule that may be effective in treating neurological symptoms associated with long COVID, including loss of smell and brain fog.

People with behavioral variant frontotemporal dementia were more likely to exhibit apathy and functional decline, even in the mildest stage of dementia, compared with patients with Alzheimer’s disease, researchers recently reported.

A blood-based biomarker test aided diagnosis and clinical management of Alzheimer’s disease by detecting brain amyloidosis in symptomatic patients, researchers reported at the Clinical Trials for Alzheimer’s Disease annual meeting.

With an estimated 1 billion people affected by migraine worldwide, there is an urgent need to provide effective treatment for this debilitating disease.

A joint letter from six major medical organizations calls on Congress to ensure patients can access affordable, quality health care.

Clinical outcome assessments currently used for people with Lennox-Gastaut syndrome and Dravet syndrome were “not fit” for evaluating non-seizure outcomes, researchers said, prompting the development of a global clinical impression measure.

Stressors in life can contribute to poor functional, cognitive and neuropsychiatric outcomes up to a year after being hospitalized with COVID-19, researchers reported in the Journal of Neurological Science.

In this edition, foslevodopa-foscarbidopa improves motor symptoms in advanced PD, posterior surgery for treating cervical radiculopathy, Tysabri favored over IV in patients with relapsing-remitting MS and more.